As Frustration Mounts Over 340B Contract Pharmacy Impasse, Arguments in Highly Anticipated AstraZeneca Lawsuit Postponed to Mid-October

Oral arguments previously scheduled for Sept. 14 in drugmaker AstraZeneca’s closely watched 340B contract pharmacy lawsuit against HHS and HRSA have been rescheduled for Oct. 18.

Oral arguments previously scheduled for Sept. 14 in drugmaker AstraZeneca’s 340B contract pharmacy lawsuit against HHS and HRSA have been rescheduled for Oct. 18. The U.S. District Court for the District of Delaware announced the new date for arguments on

Read More »

Hospital Groups Back Feds in United Therapeutics 340B Contract Pharmacy Case

United Therapeutics’ denials of and restrictions on 340B pricing involving contract pharmacies are illegal and jeopardize patient care, six hospital groups have told a federal district judge.

Drug manufacturer United Therapeutics’ (UT) denials of and restrictions on 340B drug discounts when covered entities use contract pharmacies are illegal and jeopardize patient care, six hospital groups have told a federal district judge in Washington, D.C.

The groups—American Hospital

Read More »

House Passes Framework for $3.5T Budget Bill That Will Include Key Drug Pricing Measures

The U.S. House this week passed a budget blueprint that will pave the way for a vote on a number of drug pricing measures. 340B providers hope to be spared from Medicaid pharmacy cuts.

The House of Representatives passed a $3.5 trillion budget framework bill on Tuesday that potentially clears the path for Democrats to make extensive changes to U.S. health care delivery, although the impact on the 340B program remains to be seen.

Read More »

As Biden and House Dems Prepare to Unveil Drug Pricing Plans, 340B Providers Fret Over About Lost Savings

HHS Secretary Xavier Becerra's plan to fight excessive drug prices will be published publicly in the coming weeks, a White House official said yesterday.

As President Biden and House Democrats prepare to unveil their drug pricing game plans, 340B stakeholders eagerly await word on key provisions that could either be helpful or result in significant lost revenue.  While the proposals are going to be

Read More »

Key House Democrats Keep Up Pressure on Insulin Manufacturers

U.S. House Energy & Commerce Committee Democratic leaders Frank Pallone (N.J.) and Diana DeGette (Colo.) have asked insulin manufacturers Lilly, Novo Nordisk, and Sanofi for information about their prices, revenues, and expenses.

U.S. House Energy & Commerce Committee Democratic leaders have sent letters to three major drug manufacturers demanding an explanation for the skyrocketing price of insulin. The E&C Committee has jurisdiction over the 340B program and plays an instrumental role on

Read More »

340B Entities Left Out of BMS’s $75 Million Settlement; Whistleblower Pursues Case Against Lilly

340B covered entities will get none of the $75 million Bristol Myers Squibb is paying to settle claims it underreported its average manufacturer prices (AMPs) in order to underpay Medicaid drug rebates. A whistleblower is pursuing a similar case against Lilly.

340B covered entities will get none of the $75 million Bristol Myers Squibb is paying California, 27 other states, and the federal government to settle claims it underreported its average manufacturer prices (AMPs) in order to underpay Medicaid drug rebates.

Read More »

Recent Supreme Court Ruling Could Affect 340B Dispute Resolution Lawsuits

A recent U.S. Supreme Court decision involving medical device manufacturer Arthrex could influence lawsuits over the 340B program’s administrative dispute resolution (ADR) process.

A U.S. Supreme Court decision in late June about the appointment of federal administrative patent judges (APJs) could influence the outcome of several ongoing lawsuits over the 340B program’s administrative dispute resolution (ADR) process.

On June 21, the high court

Read More »

In Strongly Worded Brief in United Therapeutics Case, Feds Defend 340B Contract Pharmacy Actions

Federal officials relied “on sound statutory interpretation and sufficient evidence” when it concluded in May that United Therapeutics (UT) broke the law when it conditioned access to 340B pricing on its products, government lawyers told a federal district judge yesterday.

Federal officials relied “on sound statutory interpretation and sufficient evidence” when it concluded in May that United Therapeutics (UT) broke the law when it conditioned access to 340B pricing on its products, government lawyers told a federal district judge in

Read More »

Feds and AstraZeneca Trade Punches in Drug Maker’s 340B Lawsuit

Drug manufacturer AstraZeneca and the federal government each told a federal district court last Friday why it, and not the other, should prevail in Astra’s lawsuit over the government’s 340B contract pharmacy requirements.

Drug manufacturer AstraZeneca and the federal government each told a federal district court last Friday why it, and not the other, should prevail in Astra’s lawsuit over the government’s 340B contract pharmacy requirements.

The Aug. 6 filings were the latest

Read More »

340B to Be Key Agenda Item for Biden’s New HHS General Counsel Pick

President Biden has nominated civil rights attorney Sam Bagenstos to be HHS General Counsel.

President Biden has nominated current White House Office of Management and Budget (OMB) General Counsel Sam Bagenstos to be the U.S. Health and Human Services Department (HHS) General Counsel—a post that has had a growing role in defending the 340B

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report

Site Footer Live